{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T20:23:43Z","timestamp":1776803023373,"version":"3.51.2"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ijcard.2024.132305","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T18:20:17Z","timestamp":1719512417000},"page":"132305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Safety evaluation of bempedoic acid: A pharmacovigilance analysis using FDA adverse event reporting system data"],"prefix":"10.1016","volume":"412","author":[{"given":"Bing","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qucheng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2023","key":"10.1016\/j.ijcard.2024.132305_bb0005","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"ESC guidelines for the management of cardiovascular disease in patients with diabetes: developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)","volume":"44","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"issue":"2020","key":"10.1016\/j.ijcard.2024.132305_bb0010","first-page":"111","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European atherosclerosis society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur. Heart J."},{"issue":"2019","key":"10.1016\/j.ijcard.2024.132305_bb0015","first-page":"e1082","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2024.132305_bb0020","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Byty\u00e7i","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2024.132305_bb0025","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"European atherosclerosis society consensus panel, statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2024.132305_bb0030","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.jacc.2013.05.050","volume":"62","author":"Ballantyne","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2024.132305_bb0035","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijcard.2024.132305_bb0040","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"CLEAR harmony trial, safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2024.132305_bb0045","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s11883-022-01054-2","article-title":"Bempedoic acid: for whom and when","volume":"24","author":"Ruscica","year":"2022","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.ijcard.2024.132305_bb0050","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s10557-021-07147-5","article-title":"Role of Bempedoic acid in clinical practice","volume":"35","author":"Ballantyne","year":"2021","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ijcard.2024.132305_bb0055","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2024.132305_bb0060","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of Bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2024.132305_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117192","article-title":"Evaluation of the efficacy and safety of bempedoic acid in women and men: pooled analyses from phase 3 trials","volume":"384","author":"Goldberg","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2024.132305_bb0070","article-title":"Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance","volume":"0","author":"Bays","year":"2023","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.ijcard.2024.132305_bb0075","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/cts.13202","article-title":"Pharmacokinetics of bempedoic acid in patients with renal impairment","volume":"15","author":"Amore","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ijcard.2024.132305_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2022.05.038","article-title":"\u2020safety and efficacy of bempedoic acid in patients with renal impairment","volume":"16","author":"Catapano","year":"2022","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.ijcard.2024.132305_bb0085","doi-asserted-by":"crossref","DOI":"10.1007\/s10557-023-07474-9","article-title":"The clinical efficacy and safety of bempedoic acid in patients at elevated risk of cardiovascular disease: a meta-analysis of randomized clinical trials","author":"Sayed","year":"2023","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ijcard.2024.132305_bb0090","doi-asserted-by":"crossref","first-page":"F1327","DOI":"10.1152\/ajprenal.00680.2010","article-title":"Avian renal proximal tubule urate secretion is inhibited by cellular stress-induced AMP-activated protein kinase","volume":"300","author":"Bataille","year":"2011","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ijcard.2024.132305_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1234601","article-title":"Untangling the relationship between bempedoic acid and gout: results from a systematic literature review","volume":"10","author":"Alunno","year":"2023","journal-title":"Front. Cardiovasc. Med."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324009276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324009276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:21:10Z","timestamp":1721348470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527324009276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":19,"alternative-id":["S0167527324009276"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.132305","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety evaluation of bempedoic acid: A pharmacovigilance analysis using FDA adverse event reporting system data","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.132305","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"132305"}}